Objective： To evaluate the clinical significance of serum sICAM-1 and bFGF change in digestive system cancers before and after intra-arterial chemotherapy. Methods：The levels of sICAM-1and bFGF of 35 patients with digestive system cancers before and after intra-arterial chemotherapy were measured by enzyme linked immunosorbent assay（ELISA） and compared with those of healthy controls. Results：The levels of sICAM-1 and bFGF of patients with digestive system cancers before intra-arterial chemotherapy were higher than those of healthy controls（P < 0.01）， and were correlated to metastasis significantly（P < 0.05）. After intra-arterial chemotherapy， the levels of sICAM-1 and bFGF were decreased（P < 0.01）. All of the patients with high level of serum sICAM-1 and bFGF before intra-arterial chemotherapy had presented with new metastasis six months later. Conclusion：Intra-arterial chemotherapy can reduce the levels of sICAM-1 and bFGF in patients with digestive system cancers. Codetermination of sICAM-1 and bFGF may be helpful to judge prognosis.